Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 5)*
|
Silence Therapeutics Plc (Name of Issuer) |
Ordinary Shares, nominal value of GBP0.05 per share (Title of Class of Securities) |
G8128Y157 (CUSIP Number) |
Richard Ian Griffiths Floor 1 Liberation Station, Esplanade St Helier, Y9, JE2 3AS 44-1534-719761 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
12/18/2024 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | G8128Y157 |
| 1 |
Name of reporting person
Richard Ian Griffiths | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
PF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
JERSEY
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
27,266,001.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
19.3 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13D
|
| CUSIP No. | G8128Y157 |
| 1 |
Name of reporting person
Ora Capital Limited | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
< br>
JERSEY
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
19,221,525.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
13.6 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
CO |
SCHEDULE 13D
|
| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
Ordinary Shares, nominal value of GBP0.05 per share |
| (b) | Name of Issuer:
Silence Therapeutics Plc |
| (c) | Address of Issuer's Principal Executive Offices:
72 Hammersmith Road, London,
UNITED KINGDOM
, W14 8TH. |
| Item 2. | Identity and Background |
| (a) | Richard Ian Griffiths |
| (b) | Floor 1 Liberation Station, Esplanade, St Helier, Jersey, JE2 4JD |
| (c) | The principal business of Ora is capital investments. The principal business of Mr. Griffiths is serving as chairman of Sarossa Plc and Ora Limited. |
| (d) | n/a |
| (e) | n/a |
| (f) | Jersey, Channel Islands |
| Item 3. | Source and Amount of Funds or Other Consideration |
Mr. Griffiths sold an aggregate of 23,064 ADSs in open market transactions between March 28, 2024 and December 10, 2024 for aggregate gross proceeds of $0.5M. Mr. Griffiths purchased an aggregate of 1,208,697 ADSs in open market transactions between March 28, 2024 and December 17, 2024 for an aggregate price of $11.6M. All purchases were for cash and were funded by companies or personal funds of Mr. Griffiths. | |
| Item 4. | Purpose of Transaction |
This Amendment does not change the information previously reported under this item. | |
| Item 5. | Interest in Securities of the Issuer |
| (a) | (a)-(b) Rows (7) through (13) of the cover pages of this Schedule 13D are hereby incorporated by reference. |
| (b) | N/A |
| (c) | (c) Except as set forth in Schedule 1, none of the Reporting Persons has effected any transactions in shares of the Issuers Common Stock during the last 60 days. |
| (d) | (d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the shares of Common Stock beneficially owned by any of the Reporting Persons. |
| (e) | N/A |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer |
n/a | |
| Item 7. | Material to be Filed as Exhibits. |
A. Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.B. Schedule 1 Transactions in ADSs During the Past Sixty Days |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|